Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Zscaler Inc (ZS) Price & Performance

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.

Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.

Zscaler (ZS) trades at $220.79, down 2.21% on the day, amid mixed signals. The stock shows strong technical momentum with bullish moving averages, but RSI suggests potential overbought conditions. Fundamentally, revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net income margin of -1.88%. Recent news includes executive changes and an upcoming Investor Day on October 6, 2026.

The outlook is cautiously optimistic. Analyst consensus is strongly bullish with a $222.83 price target, but risks include persistent losses, competitive pressures, and insider selling. Upside hinges on AI-driven bookings growth and execution stability post-CRO transition. Investors should weigh high valuation multiples against the company's growth trajectory and market position in cybersecurity.